Researchers from ARUP Institute for Clinical and Experimental Pathology and the University of Utah have tested to establish if D&S provides acceptable data when compared to an existing, validated, solid phase extraction (SPE) procedure for opioids in urine samples. In their findings, D&S underestimated oxycodone concentrations in a sample as much as 45% compared to the existing method utilising SPE sample preparation.
They emphasize the importance of investigating matrix effects early on in the method validation process on a large number of specimens, in order to determine whether D&S sample preparation is adequate or whether more comprehensive sample preparation such as SPE is necessary.
Or, as an end user puts it: "OK so you’ve just bought a $300k mass spec. Now you're literally going to urinate in the front end of it. Doesn’t sound so good now does it?"
Achieve Highly Pure Peptides Using High Performance Flash Chromatography
White Paper from Biotage: Practical Considerations Using Quantisal® Oral Fluid Collection Devices
New UV Monitor Kit for Large Scale Purification
Peptide Workflow by Biotage
Thank you for visiting our Analytica Booth